BHCM
TVTX icon

Brevan Howard Capital Management’s Travere Therapeutics TVTX Stock Holding History

Brevan Howard Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,067
Closed -$1.11M – 2503
2025
Q4 		$1.11M Sell
29,067
-13,438
-32% -$437K 0.01% 716
2025
Q3 		$1.02M Buy
+42,505
New +$799K ﹤0.01% 882
2025
Q1 		– Sell
-30,953
Closed -$539K – 1465
2024
Q4 		$539K Sell
30,953
-30,742
-50% -$544K ﹤0.01% 594
2024
Q3 		$863K Buy
61,695
+400
+0.7% +$4.17K 0.01% 499
2024
Q2 		$504K Buy
61,295
+12,701
+26% +$85.5K ﹤0.01% 604
2024
Q1 		$375K Buy
48,594
+25,553
+111% +$216K ﹤0.01% 564
2023
Q4 		$207K Buy
+23,041
New +$168K ﹤0.01% 870

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Brevan Howard Capital Management's TVTX Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 29,067 shares — an estimated $1.11M sold.

Brevan Howard Capital Management first reported a position in TVTX in Q4 2023 and held it in 7 quarters. The position peaked at $1.11M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 29,067 Travere Therapeutics shares in Q1 2026, an estimated $1.11M.
  • Brevan Howard Capital Management first reported a position in Travere Therapeutics in Q4 2023 and held it in 7 quarters.
  • Brevan Howard Capital Management's Travere Therapeutics position peaked at $1.11M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.